Haematologica · 2021 · 76 citations · 36 references
MedicineHematologyImmunologyHematologic OncologyImmunotherapyTransplant ImmunologyAllogeneic Stem Cell TransplantationGraft-versus-host DiseaseHematopoietic Stem Cell TransplantationTransplant ComplicationsTransplant OutcomesTransplant SurvivalGraft-versus-host Disease GradingGraft-versus-host Disease-related SurvivalHematologic AbnormalitiesSurvival After Allogeneic TransplantationSurvival RatesTransplantation For Hematologic MalignanciesTransplantation Outcome AssessmentUnrelated Donation
Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome following allogeneic hematopoietic cell transplantation though advances in prophylaxis and supportive care have been made. The aim of this study is to test whether the incidence and mortality of aGvHD have decreased over time. 102,557 patients with a median age of 47.6 years and with malignancies after first allogeneic sibling or unrelated donor (URD) transplant were studied in the following periods: 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015. Findings: 100-day incidences of aGvHD grades II-IV decreased from 40% to 38%, 32%, 29% and 28%, respectively, over calendar time (P<0.001). In multivariate analysis URD, not in complete remission (CR) at transplant or untreated, and female donor for male recipient were factors associated with increased risk whereas the use of ATG/alemtuzumab decreased aGvHD incidence. Median follow-up was 214, 169, 127, 81 and 30 months, respectively, for the periods analyzed. Three-year-survival after aGvHD grades II-IV increased significantly from 38% to 40%, 43%, 44%, and 45%, respectively. In multivariate analysis URD, not in CR at transplant, peripheral blood as stem cell source, female donor for male recipient, and the use of ATG/alemtuzumab were associated with increased mortality whereas reduced-intensity conditioning was linked to lower mortality. Mortality increased with increasing patient age but decreased in the recent cohorts. Our analysis demonstrates that aGvHD has decreased over recent decades and also that the survival rates of patients affected with aGvHD has improved.
36
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka, Daniel Weisdorf, Peyton Martin et al. · PubMed · 1995 · 5.1K citations
Leo Luznik, Paul V. O’Donnell, Heather J. Symons et al. · Biology of Blood and Marrow Transplantation · 2008 · 1.9K citations · Full text
Medicine, Hematology, Oncology +16
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Ted Gooley, Jason W. Chien, Steven A. Pergam et al. · New England Journal of Medicine · 2010 · 1.5K citations · Full text
Medicine, Hematology, Surgery +17
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti, Brent R. Logan, Stephanie J. Lee et al. · New England Journal of Medicine · 2012 · 905 citations · Full text
Medicine, Hematology, Immunology +15
Jürgen Finke, Wolfgang Bethge, Claudia Schmoor et al. · The Lancet Oncology · 2009 · 719 citations